Authors/Disclosures
|
|
No disclosure on file |
|
Kimford J. Meador, MD, FAAN
(Stanford University School of Medicine)
|
The institution of Dr. Meador has received research support from NIH. The institution of Dr. Meador has received research support from Eisai. The institution of Dr. Meador has received research support from Medtronics. The institution of Dr. Meador has received research support from The Epilepsy Consortium. |
|
|
No disclosure on file |
|
Andres M. Kanner, MD, FAAN
(University of Miami, Miller School of Medicine, Department of Neurology)
|
Dr. Kanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Kanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon. Dr. Kanner has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsy Foundation of America. Dr. Kanner has received personal compensation in the range of $500-$4,999 for serving as a Lecture at International meeting with Eisai. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Dale C. Hesdorffer
(Columbia University)
|
No disclosure on file |
|
|
No disclosure on file |
|
Patricia E. Penovich, MD, FAAN
(Patricia E Penovich LLC)
|
Dr. Penovich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Engage therapeutics. Dr. Penovich has received personal compensation in the range of $0-$499 for serving as a Consultant for LVIS. Dr. Penovich has received personal compensation in the range of $0-$499 for serving as a Consultant for Monteris. Dr. Penovich has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SK Therapeutics. Dr. Penovich has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Penovich has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Greenwich. Dr. Penovich has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SK Biosciences. Dr. Penovich has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis. Dr. Penovich has a non-compensated relationship as a Comittee Member with American Epilepsy Society that is relevant to AAN interests or activities. |
|
Michael R. Sperling, MD, FAAN
(Thomas Jefferson University)
|
Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. The institution of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for International Medical Press. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Projects for Knowledge. The institution of Dr. Sperling has received research support from SK Life Science. The institution of Dr. Sperling has received research support from UCB Pharma . The institution of Dr. Sperling has received research support from Takeda. The institution of Dr. Sperling has received research support from Neurelis. The institution of Dr. Sperling has received research support from Engage Therapeutics . The institution of Dr. Sperling has received research support from Medtronic. The institution of Dr. Sperling has received research support from Cavion. The institution of Dr. Sperling has received research support from Xenon Pharma. The institution of Dr. Sperling has received research support from Cerevel. The institution of Dr. Sperling has received research support from National Institutes of Health . The institution of Dr. Sperling has received research support from DARPA. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Vice President with Epilepsy Consortium . |
|
|
No disclosure on file |
|
Kevin McKenna, PhD
(Zeneca Pharmaceuticals)
|
No disclosure on file |
|
Melodie R. Winawer, MD, MS
(Columbia Univ)
|
Dr. Winawer has nothing to disclose. |
|
|
No disclosure on file |